MedImmune’s CEO Stepping Down
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca’s North American CEO Zook will assume responsibilities until a successor is hired.
You may also be interested in...
AstraZeneca appoints Fante to head U.S.
U.K drug maker names Rich Fante to U.S. President Nov. 13. Fante, a 13-year veteran of the firm, was most recently VP-brand strategy and portfolio operations, leading development and marketing for all AstraZeneca brands in the U.S. Fante takes the helm from Tony Zook, CEO of North America and head of global marketing, whose role was expanded in July to include oversight of MedImmune after CEO David Mott left the firm one year after AstraZeneca's $15.6 billion buyout (1"The Pink Sheet" DAILY, June 26, 2008)
AstraZeneca appoints Fante to head U.S.
U.K drug maker names Rich Fante to U.S. President Nov. 13. Fante, a 13-year veteran of the firm, was most recently VP-brand strategy and portfolio operations, leading development and marketing for all AstraZeneca brands in the U.S. Fante takes the helm from Tony Zook, CEO of North America and head of global marketing, whose role was expanded in July to include oversight of MedImmune after CEO David Mott left the firm one year after AstraZeneca's $15.6 billion buyout (1"The Pink Sheet" DAILY, June 26, 2008)
Roche’s High Stakes Gambit For Genentech
With Roche's unsolicited attempt to buy out Genentech's minority shareholders for $89 dollars a share, a bid totaling nearly $44 billion, the company is wagering heavily that it will not destroy one of the industry's most successful pharma-biotech collaborations. But has Roche laid out a straight flush or lost its ace to a bluff